Osteoporosis is a bone disease that is characterised by a progressive decrease in bone mass and alteration in bone microarchitecture, which can lead to skeletal system impairment and an increased risk of fracture. It is estimated, that more than 200 million women worldwide is affected by osteoporosis and the direct costs of treatment of fractures caused by osteoporosis reach 10-15 billion dollars yearly in USA alone. Osteoporosis, like other diseases associated with bone loss, is chronic disease requiring permanent treatment. There are some anti-osteoporotic drugs on the market, however due to their insufficient efficiency, side effects and uncomfortably frequent application, there is a need for the development of new compounds capable of inhibiting bone resorption, having a good gastrointestinal absorption and not causing the decrease in bone mineralisation.
For the commercialisation we offer a novel class of bisphosphonate compounds being the promising candidates for anti-osteoporotic drugs. Those compounds show very favourable inhibitory effect on bone resorption properties with the participation of osteoclasts.
The developed bisphosphonates show higher biological activity as compared to known bisphosphonate drugs. The tests conducted on cell lines as well as on the animals showed, that offered compounds have anti-osteoporotic effect even with the once a week administration. Bone repairing process has been observed with the new structures of bone tissue. Importantly, ultrastructural and histological analyses showed that the elaborated compounds do not cause the development of necrosis process, which is one of the most severe side effects of bisphosphonates administration.
- Treatment and prophylaxis of osteoporosis
- Therapy of other diseases associated with incorrect bone resorption, such as Paget’s disease, prosthesis-related bone loss or osteolysis as well as the hypercalcemia in cancer disease
Posted by Agata Kołacz, Posted on 20.05.2016